R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20
Publication: Journal of Comparative Effectiveness Research
Abstract
In this update, we examine Canada’s Drug Agency position statement on artificial intelligence in evidence generation, a systematic review of clinical trial data linkage approaches, and real-world effectiveness evidence from England’s respiratory syncytial virus vaccination program.
Formats available
You can view the full content in the following formats:
References
1.
CDA-AMC. New position statement aims to guide the use of AI methods in health technology assessment. Available from: https://www.cda-amc.ca/news/new-position-statement-aims-guide-use-ai-methods-health-technology-assessment
2.
NICE. Use of AI in evidence generation: NICE position statement. Available from: https://www.nice.org.uk/about/what-we-do/our-research-work/use-of-ai-in-evidence-generation--nice-position-statement
3.
Arora P, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17. J. Comp. Eff. Res. 14(1), e240212 (2025).
4.
Government of Canada. Artificial Intelligence and Data Act. Available from: https://ised-isde.canada.ca/site/innovation-better-canada/en/artificial-intelligence-and-data-act
5.
Reason T, Klijn S, Rawlinson W et al. Using generative artificial intelligence in health economics and outcomes research: a primer on techniques and breakthroughs. Pharmacoecon. Open 9(4), 501–517 (2025).
6.
Najafzadeh M, Fernández Oromendia A, Burcu M et al. Linkage of clinical trial data to routinely collected data sources: a scoping review. JAMA Netw. Open 8(4), e257797 (2025).
7.
Brüssow H. Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned. Microlife 6, uqaf003 (2025).
8.
Department of Health and Social Care (UK). Respiratory syncytial virus (RSV) immunisation programme for infants and older adults: JCVI full statement. (2023). Available from: https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023
9.
Mensah AA, Whitaker H, Andrews NJ, Watson CH. Early impact of RSV vaccination in older adults in England. Lancet 405(10485), 1139–1140 (2025).
Information & Authors
Information
Published In
Copyright
© 2025 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 3 July 2025
Accepted: 8 July 2025
Published online: 23 July 2025
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20. (2025) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2025-0113
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Paul Arora, Sreeram V Ramagopalan, R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 23, Journal of Comparative Effectiveness Research, 10.57264/cer-2025-0196, 15, 1, (2025).